Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Am J Respir Crit Care Med ; 187(7): 736-42, 2013 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-23328529

RESUMO

RATIONALE: Current clinical prediction scores for acute lung injury (ALI) have limited positive predictive value. No studies have evaluated predictive plasma biomarkers in a broad population of critically ill patients or as an adjunct to clinical prediction scores. OBJECTIVES: To determine whether plasma angiopoietin-2 (Ang-2), von Willebrand factor (vWF), interleukin-8 (IL-8), and/or receptor for advanced glycation end products (sRAGE) predict ALI in critically ill patients. METHODS: Plasma samples were drawn from critically ill patients (n = 230) identified in the emergency department. Patients who had ALI at baseline or in the subsequent 6 hours were excluded, and the remaining patients were followed for development of ALI. MEASUREMENTS AND MAIN RESULTS: Nineteen patients developed ALI at least 6 hours after the sample draw. Higher levels of Ang-2 and IL-8 were significantly associated with increased development of ALI (P = 0.0008, 0.004, respectively). The association between Ang-2 and subsequent development of ALI was robust to adjustment for sepsis and vasopressor use. Ang-2 and the Lung Injury Prediction Score each independently discriminated well between those who developed ALI and those who did not (area under the receiver operating characteristic curve, 0.74 for each), and using the two together improved the area under the curve to 0.84 (vs. 0.74, P = 0.05). In contrast, plasma levels of sRAGE and vWF were not predictive of ALI. CONCLUSIONS: Plasma biomarkers such as Ang-2 can improve clinical prediction scores and identify patients at high risk for ALI. In addition, the early rise of Ang-2 emphasizes the importance of endothelial injury in the early pathogenesis of ALI.


Assuntos
Lesão Pulmonar Aguda/sangue , Angiopoietina-2/sangue , Interleucina-8/sangue , Receptores Imunológicos/sangue , Fator de von Willebrand/análise , Lesão Pulmonar Aguda/fisiopatologia , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/sangue , Estado Terminal , Técnicas de Apoio para a Decisão , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Curva ROC , Receptor para Produtos Finais de Glicação Avançada , Análise de Regressão , Fatores de Risco , Sensibilidade e Especificidade
2.
J Immunol ; 169(10): 5962-70, 2002 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-12421982

RESUMO

The complement-derived anaphylatoxin, C5a, is a potent phlogistic molecule that mediates its effects by binding to C5a receptor (C5aR; CD88). We now demonstrate specific binding of radiolabeled recombinant mouse C5a to mouse dermal microvascular endothelial cells (MDMEC) with a K(d50) of 3.6 nM and to approximately 15,000-20,000 receptors/cell. Recombinant mC5a competed effectively with binding of [(125)I]rmC5a to MDMEC. Enhanced binding of C5a occurred, as well as increased mRNA for C5aR, after in vitro exposure of MDMEC to LPS, IFN-gamma, or IL-6 in a time- and dose-dependent manner. By confocal microscopy, C5aR could be detected on surfaces of MDMEC using anti-C5aR Ab. In vitro expression of macrophage inflammatory protein-2 (MIP-2) and monocyte chemoattractant protein-1 (MCP-1) by MDMEC was also measured. Exposure of MDMEC to C5a or IL-6 did not result in changes in MIP-2 or MCP-1 production, but initial exposure of MDMEC to IL-6, followed by exposure to C5a, resulted in significantly enhanced production of MIP-2 and MCP-1 (but not TNF-alpha and MIP-1alpha). Although LPS or IFN-gamma alone induced some release of MCP-1 and MIP-2, pre-exposure of these monolayers to LPS or IFN-gamma, followed by addition of C5a, resulted in synergistic production of MIP-2 and MCP-1. Following i.v. infusion of LPS into mice, up-regulation of C5aR occurred in the capillary endothelium of mouse lung, as determined by immunostaining. These results support the hypothesis that C5aR expression on MDMEC and on the microvascular endothelium of lung can be up-regulated, suggesting that C5a in the co-presence of additional agonists may mediate pro-inflammatory effects of endothelial cells.


Assuntos
Antígenos CD/biossíntese , Antígenos CD/fisiologia , Complemento C5a/metabolismo , Endotélio Vascular/imunologia , Endotélio Vascular/metabolismo , Receptores de Complemento/biossíntese , Receptores de Complemento/fisiologia , Adjuvantes Imunológicos/farmacologia , Sequência de Aminoácidos , Animais , Antígenos CD/imunologia , Antígenos CD/metabolismo , Ligação Competitiva/imunologia , Células Cultivadas , Quimiocina CCL2/biossíntese , Quimiocina CXCL2 , Quimiocinas/biossíntese , Endotélio Vascular/citologia , Citometria de Fluxo , Técnica Direta de Fluorescência para Anticorpo , Regulação da Expressão Gênica/imunologia , Infusões Intravenosas , Interferon gama/farmacologia , Interleucina-6/farmacologia , Radioisótopos do Iodo/metabolismo , Lipopolissacarídeos/administração & dosagem , Lipopolissacarídeos/farmacologia , Pulmão/irrigação sanguínea , Pulmão/imunologia , Pulmão/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Endogâmicos DBA , Microcirculação/citologia , Microcirculação/imunologia , Microcirculação/metabolismo , Microscopia Confocal , Dados de Sequência Molecular , Fragmentos de Peptídeos/análise , Fragmentos de Peptídeos/metabolismo , RNA Mensageiro/biossíntese , Receptor da Anafilatoxina C5a , Receptores de Complemento/imunologia , Receptores de Complemento/metabolismo , Regulação para Cima/imunologia , Fator de von Willebrand/metabolismo
3.
Am J Pathol ; 160(5): 1867-75, 2002 May.
Artigo em Inglês | MEDLINE | ID: mdl-12000738

RESUMO

Sepsis and trauma are the two most common causes of disseminated intravascular coagulation and multiple organ dysfunction syndrome. Both disseminated intravascular coagulation and the systemic inflammatory response syndrome often lead to multiple organ dysfunction syndrome. The current studies have evaluated the relationship between the anaphylatoxin, C5a, and changes in the coagulation/fibrinolytic systems during the cecal ligation and puncture (CLP) model of sepsis in rats. CLP animals treated with anti-C5a had a much improved number of survivors (63%) compared to rats treated with pre-immune IgG (31%). In CLP rats treated with pre-immune IgG there was clearly increased procoagulant activity with prolongation of the activated partial thromboplastin time and prothrombin time, reduced platelet counts, and increased levels of plasma fibrinogen. Evidence for thrombin formation was indicated by early consumption of factor VII:C, subsequent consumption of factors XI:C and IX:C and anti-thrombin and increased levels of the thrombin-anti-thrombin complex and D-dimer. Limited activation of fibrinolysis was indicated by reduced plasma levels of plasminogen and increased levels of tissue plasminogen activator and plasminogen activator inhibitor. Most of these parameters were reversed in CLP rats that had been treated with anti-C5a. Production of C5a during sepsis may directly or indirectly cause hemostatic defects that can be reduced by blockade of C5a.


Assuntos
Anticorpos Monoclonais/farmacologia , Fatores de Coagulação Sanguínea/efeitos dos fármacos , Complemento C5a/imunologia , Sepse/sangue , Animais , Anticorpos Monoclonais/imunologia , Antitrombinas/efeitos dos fármacos , Antitrombinas/metabolismo , Fatores de Coagulação Sanguínea/metabolismo , Complemento C5a/química , Modelos Animais de Doenças , Fator IX/efeitos dos fármacos , Fator IX/metabolismo , Fator V/efeitos dos fármacos , Fator V/metabolismo , Fator VII/efeitos dos fármacos , Fator VII/metabolismo , Fator VIII/efeitos dos fármacos , Fator VIII/metabolismo , Fator XI/efeitos dos fármacos , Fator XI/metabolismo , Fator XII/efeitos dos fármacos , Fator XII/metabolismo , Produtos de Degradação da Fibrina e do Fibrinogênio/efeitos dos fármacos , Produtos de Degradação da Fibrina e do Fibrinogênio/metabolismo , Fibrinogênio/efeitos dos fármacos , Fibrinogênio/metabolismo , Fibrinólise/efeitos dos fármacos , Masculino , Tempo de Tromboplastina Parcial , Fragmentos de Peptídeos/imunologia , Contagem de Plaquetas , Tempo de Protrombina , Ratos , Ratos Long-Evans , Sepse/mortalidade , Organismos Livres de Patógenos Específicos , Taxa de Sobrevida , Trombina/efeitos dos fármacos , Trombina/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...